Michelle Melisko

City College of San Francisco — United States

Medicine · Health Sciences

52h-index11.1kcitations334works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(82), Breast Cancer Treatment Studies(67), Cancer survivorship and care(64), HER2/EGFR in Cancer Research(59), Brain Metastases and Treatment(53)

Publications332 total

Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer
npj Breast Cancer·2025Open Access
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer
npj Breast Cancer·2025Open Access
CTNI-73. LAT1 EXPRESSION SCALE AND ADAPTIVE DESIGN FOR A PHASE IIA TRIAL OF QBS72S IN BREAST CANCER BRAIN METASTASES
Neuro-Oncology·2025Open Access
Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study
Breast Cancer Research·2025Open Access
Understanding Associations Between Patient‐Level Factors and Participation in a Breast Cancer Clinical Trial
UNC Libraries·2025Open Access
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases
BMC Cancer·2025· 1 citedOpen Access
Understanding Associations Between Patient‐Level Factors and Participation in a Breast Cancer Clinical Trial
Cancer Medicine·2025Open Access
TRLS-13 CLINICAL CHARACTERISTICS AND OVERALL SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER AND BRAIN METASTASES: A SINGLE CENTER RETROSPECTIVE COHORT STUDY
Neuro-Oncology Advances·2025Open Access
Abstract P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study
Clinical Cancer Research·2025
Abstract P5-12-25: Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer
Clinical Cancer Research·2025
Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study
Clinical Cancer Research·2025
Abstract P1-12-05: Improving Outcomes in Patients With High-risk Breast Cancer: Outcomes and Analysis From an Educational Program on HR+/HER2- Early and Metastatic Breast Cancer
Clinical Cancer Research·2025
Abstract P5-10-01: Demographic, Clinical Characteristics, and Overall Survival of Patients with Metastatic Breast Cancer and Brain Metastases: A Single Center Retrospective Cohort Study
Clinical Cancer Research·2025
Abstract PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study
Clinical Cancer Research·2025
Abstract P3-08-17: TBCRC 058: A Randomized Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, & Treatment of Physician’s Choice in Patients with Androgen Receptor-Positive Metastatic Triple-Negative or Estrogen Receptor-Low Breast Cancer (NCT06099769)
Clinical Cancer Research·2025
Abstract PS5-05: Late-onset immune toxicity incidence & risk factors in breast cancer: a multi-institutional study
Clinical Cancer Research·2025
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
JCO Precision Oncology·2025· 4 citedOpen Access
Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
Journal of Clinical Oncology·2025
Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study.
Journal of Clinical Oncology·2025· 8 cited
Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
Journal of Clinical Oncology·2025
page 1 of 17Next →

Frequent Co-authors

Hope S. Rugo(17), A. Jo Chien(13), Laura J. Esserman(13), Mindy Goldman(11), Rita Nanda(10), Debra L. Friedman(10), Kathi Mooney(10), Tracey L. O’Connor(10), Electra D. Paskett(10), Phyllis C. Zee(10), Nicole R. McMillian(10), Deborah A. Freedman-Cass(10), Judy C. Boughey(9), Crystal S. Denlinger(9), Wendy Demark‐Wahnefried(9), Linda Overholser(9), Karen L. Syrjala(9), Minetta C. Liu(8), Christina Yau(8), Kathy S. Albain(8)